Application of vitamin D, Russian drug Osteo-Vit D3 in the complex prevention of osteoporosis and osteoporotic fractures in children and teenagers

DOI: https://doi.org/10.29296/25419218-2022-02-01
Issue: 
2
Year: 
2022

D.V. Dedov(1, 2)
1-Tver State Medical University of the Ministry of Health of the Russian Federation, Sovetskaya str., 4, Tver, 170100, Russia ;
2-Regional Clinical Cardiological Dispensary, Komsomolsky Avenue, 19, Tver, 170041, Russia

Objective of the study. To carry out the analysis of the literature data devoted to the problem of diagnostics, pathogenesis, clinic of osteoporosis and osteoporosis fractures in children and teenagers, complex prevention of osteoporosis and osteoporosis fractures with the use of calcium (Ca), vitamin D, Osteo-Vit D3. Material and methods. The authors have studied 20 foreign articles by authors from India, Australia, Canada, Spain, the USA, Great Britain, the Netherlands, New Zealand, China, Ireland and 20 Russian publications which regard the problem of prevention of osteoporosis and osteoporosis fractures, including in children and teenagers with application of Ca, vitamin D as well as the Russian preparation Osteo-Vit D3. Results. The authors observed that 50% of children under 18 years of age suffered fractures. The study showed that deformities and fractures of the vertebral bodies were a specific feature of the course of osteoporosis in children associated with hormone therapy. They found that 38% of children had vitamin D deficiency. Found associations of low vitamin D levels and recurrent osteoporotic fractures. Revealed that vitamin D is essential for normal body Ca homeostasis and bone metabolism. Reflected data on the importance of Ca and vitamin D preparations in increasing bone mineral density and preventing osteoporosis. Found that vitamin D supplementation was associated with a decreased risk of fracture. Recommended supplementation with Ca and vitamin D to prevent osteoporotic fractures. We studied the effectiveness of the Russian drug Osteo-Vit D3 in comparison with foreign analogues. It was obtained that prescription of Osteo-Vit D3 was associated with an increase in bone mineral density and a reduced risk of fractures. By its properties Osteo-Vit D3 was not inferior to foreign Calcemin preparations. Conclusions. Thus, Osteo vit D3 is a promising preparation for increase of mineral density of bone tissue, strength of bones, prevention of osteoporosis and osteoporosis fractures in children and teenagers. In addition, Osteo-Vit D3 was developed by Russian scientists and its properties are not inferior to the foreign drug Calcemin.
Keywords: 
Key words: children
teenagers
osteoporosis
fractures
prevention
Osteo-Vit D3.
References: 
  1. Белая Ж.Е., Рожинская Л.Я., Гребенникова Т.А. и др. Краткое изложение проекта федеральных клинических рекомендаций. по остеопорозу. Остеопороз и остеопатии. 2020; 23 (2): 4–21. [Belaya J.E., Rozhinskaya L.Y., Grebennikova T.A. et al. Summary of the draft of the federal clinical guidelines. on osteoporosis. Osteoporosis and osteopathies. 2020; 23 (2): 4–21. DOI: 10.14341/osteo12373 (in Russian)].
  2. Seuffert P., Sagebien C.A., McDonnell M. et al. Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice. Arch Osteoporos. 2016; 11: 10. DOI: 10.1007/s11657-016-0262-7.
  3. Трифонов В., Елистратов Д. Рекомендации по лечению остеопороза в условиях коморбидности и полипрагмазии с помощью препарата «ОСТЕОМЕД ФОРТЕ» и фитопрепаратов. Врач. 2018; 5: 87–8. [Trifonov V., Elistratov D. Recommendations for the treatment of osteoporosis in conditions of comorbidity and polypragmasy with OSTEOMED FORTE and phytopreparations. Vrach. 2018; 5: 87–8 (in Russian)]
  4. Клинические рекомендации. Остеопороз. Утверждены Минздравом РФ. 2021; 82. [Clinical guidelines. Osteoporosis. Approved by the Ministry of Health of the Russian Federation. 2021; 82 (in Russian)].
  5. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017; 63 (6): 392–426. [Melnichenko G.A., Belaya J.E., Rozhinskaya L.Y. et al. Federal clinical guidelines for the diagnosis, treatment and prevention of osteoporosis. Problems of Endocrinology. 2017; 63 (6): 392–426. DOI: 10.14341/probl2017636392-426 (in Russian)].
  6. Делягин В. Остеопения и остеопороз и их терапия в амбулаторных условиях. Врач. 2015; 11: 31–6. [Delyagin V. Osteopenia and osteoporosis and their therapy in outpatient settings. Vrach. 2015; 11: 31–6 (in Russian)]
  7. Осадчий А., Зельтер П. Двуэнергетическая рентгеновская абсорбциометрия в оценке эффективности лечения остеопении. Врач. 2015; 11: 79–80. [Osadchy A., Zelter P. Dual-energy X-ray absorptiometry in assessing the effectiveness of osteopenia treatment. Vrach. 2015; 11: 79–80 (in Russian)]
  8. Galindo-Zavala R., Bou-Torrent R., Magallares-López B. et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020; 18 (1): 20. DOI: 10.1186/s12969-020-0411-9.
  9. Grover M., Bachrach L.K. Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment. Curr Osteoporos Rep. 2017; 15 (4): 271–82. DOI: 10.1007/s11914-017-0371-2.
  10. Юрова О., Марченкова Л. Опыт применения БАД Остеомед Форте в комплексной программе реабилитации пациентов с переломом дистального отдела предплечья на фоне системного остеопороза. Врач. 2020; 2: 47–52. [Yurova O., Marchenkova L. Experience of Osteomed Forte in a comprehensive program of rehabilitation of patients with distal forearm fracture against systemic osteoporosis. Vrach. 2020; 2: 47–52. https://doi.org/10.29296/25877305-2020-02-11 (in Russian)]
  11. Кокорева И., Кореньков А., Соловьев И. Влияние препарата Остеомед Форте на сроки консолидации переломов костей у детей и подростков. Врач. 2020; 1: 82–5. [Kokoreva I., Korenkov A., Solovyov I. Effect of the drug Osteomed Forte on the consolidation time of bone fractures in children and adolescents. Vrach. 2020; 1: 82–5. https://doi.org/10.29296/25877305-2020-01-18. (in Russian)]
  12. Павлова Т., Башук И. Клинико-морфологические особенности дегенеративных изменений костной ткани на фоне остеопороза в возрастном аспекте. Врач. 2019; 6: 47–50. [Pavlova T., Bashuk I. Clinical and morphological features of degenerative changes in bone tissue against osteoporosis in the age aspect. Vrach. 2019; 6: 47–50. https://doi.org/10.29296/25877305-2019-06-11 (in Russian)]
  13. Дедов Д.В. Анализ эффективности препаратов Остеомед и Остеомед Форте в лечении остеопоротических переломов различной локализации. Врач. 2021; 11: 73–6. [Dedov D.V. Analysis of the effectiveness of Osteomed and Osteomed Forte in the treatment of osteoporotic fractures of various localizations. Vrach. 2021; 11: 73–6. https://doi.org/10.29296/25877305-2021-11-15 (in Russian)]
  14. Перльмуттер О.А., Яриков А.В., Лобанов И.А. и др. Остеопороз: текущее состояние проблемы, современные методы нейровизуализации и принципы лечения. Врач. 2020; 12: 52–60. [Perlmutter O.A., Yarikov A.V., Lobanov I.A. et al. Osteoporosis: current state of the problem, modern methods of neuroimaging and principles of treatment. Vrach. 2020; 12: 52–60. https://doi.org/10.29296/25877305-2020-12-11 (in Russian)]
  15. Пешехонова Л.К., Пешехонов Д.В., Красюков П.А. Клиническая эффективность применения препаратов Остеомед, Остеомед Форте, Остео-Вит D3 у больных вторичным остеопорозом при ревматоидном артрите. Врач. 2020; 4: 68–74. [Peshekhonova L.K., Peshekhonov D.V., Krasyukov P.A. Clinical efficacy of Osteomed, Osteomed Forte, Osteo-Vit D3 in patients with secondary osteoporosis in rheumatoid arthritis. Vrach. 2020; 4: 68–74. https://doi.org/10.29296/25877305-2020-04-12. (in Russian)]
  16. Дедов Д.В. Применение препаратов Остеомед, Остеомед Форте и Остео-Вит D3 у пациентов с остеопорозом: комплексное лечение и профилактика переломов. Врач. 2021; 12: 83–5. [Dedov D.V. Application of Osteomed, Osteomed Forte and Osteo-Vit D3 in patients with osteoporosis: comprehensive treatment and prevention of fractures. Vrach. 2021; 12: 83–5. https://doi.org/10.29296/25877305-2021-12-14 (in Russian)]
  17. Ярмолович Р.А., Салаев А.В. Улучшение регенераторной способности костной ткани при диафизарных переломах трубчатых костей на фоне применения Остеомед Форте. Врач. 2020; 5: 63–6. [Yarmolovich R.A., Salaev A.V. Improvement of regenerative capacity of bone tissue in diaphyseal fractures of tubular bones against the background of Osteomed Forte. Vrach. 2020; 5: 63–6. https://doi.org/10.29296/25877305-2020-05-14 (in Russian)]
  18. Högler W., Ward L. Osteoporosis in Children with Chronic Disease. Endocr Dev. 2015; 28: 176–95. DOI: 10.1159/000381045.
  19. Jayasena A., Atapattu N., Lekamwasam S. Treatment of glucocorticoid-induced low bone mineral density in children: a systematic review. Int J Rheum Dis. 2015; 18 (3): 287–93. DOI: 10.1111/1756-185X.
  20. Harvey N.C., Biver E., Kaufman J.M. et al. The role of calcium supplementation in healthy musculoskeletal ageing : An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int. 2017; 28 (2): 447–62. DOI: 10.1007/s00198-016-3773-6.
  21. Прохоров М., Кислов А., Елистратов Д. и др. Влияние Остеомеда на консолидацию переломов костей. Врач. 2016; 2: 68–9. [Prokhorov M., Kislov A., Elistratov D. et al. Effect of Osteomed on the consolidation of bone fractures. Vrach. 2016; 2: 68–9 (in Russian)].
  22. Струков В., Елистратов Д., Балыкова Л. и др. Переломы костей у детей и подростков – интегральный показатель остеопороза. Врач. 2015; 1: 17–20. [Strukov V., Elistratov D., Balykova L. et al. Bone fractures in children and adolescents – an integral indicator of osteoporosis. Vrach. 2015; 1: 17–20 (in Russian)].
  23. Wood C.L., Ahmed S.F. Bone protective agents in children. Arch Dis Child. 2018; 103 (5): 503–8. DOI: 10.1136/archdischild-2016-311820.
  24. Korula S., Titmuss A.T., Biggin A. et al. A Practical Approach to Children with Recurrent Fractures. Endocr Dev. 2015; 28: 210–25. DOI: 10.1159/000381047.
  25. Ward L.M. Glucocorticoid-Induced Osteoporosis: Why Kids Are Different. Front Endocrinol. (Lausanne). 2020; 11: 576. DOI: 10.3389/fendo.2020.00576.
  26. Ma J., Siminoski K., Wang P. et al; Canadian STOPP Consortium. The Accuracy of Incident Vertebral Fracture Detection in Children Using Targeted Case-Finding Approaches. J Bone Miner Res. 2021; 36 (7): 1255–68. DOI: 10.1002/jbmr.4294.
  27. Ferrer F.S., Castell E.C., Marco F.C. et al. Influence of weight status on bone mineral content measured by DXA in children. BMC Pediatr. 2021; 21 (1): 185. DOI: 10.1186/s12887-021-02665-5.
  28. Minkowitz B., Cerame B., Poletick E. et al.; Morris-Essex Pediatric Bone Health Group. Low Vitamin D Levels are Associated With Need for Surgical Correction of Pediatric Fractures. J. Pediatr Orthop. 2017; 37 (1): 23–9. DOI: 10.1097/BPO.0000000000000587.
  29. Yao P., Bennett D., Mafham M. et al. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; 2 (12): e1917789. DOI: 10.1001/jamanetworkopen.2019.17789.
  30. Gorter E.A., Oostdijk W., Felius A. et al. Vitamin D Deficiency in Pediatric Fracture Patients: Prevalence, Risk Factors, and Vitamin D Supplementation. J Clin Res Pediatr Endocrinol. 2016; 8 (4): 445–51. DOI: 10.4274/jcrpe.3474.
  31. Delshad M., Beck K.L., Conlon C.A. et al. Fracture risk factors among children living in New Zealand. J Steroid Biochem Mol Biol. 2020; 200: 105655. DOI: 10.1016/j.jsbmb.2020.105655.
  32. Soininen S., Eloranta A.M., Lindi V. et al. Determinants of serum 25-hydroxyvitamin D concentration in Finnish children: the Physical Activity and Nutrition in Children (PANIC) study. Br. J. Nutr. 2016; 115 (6): 1080–91. DOI: 10.1017/S0007114515005292.
  33. Yang G., Lee W.Y.W., Hung A.L.H. et al. Association of serum 25(OH) Vit-D levels with risk of pediatric fractures: a systematic review and meta-analysis. Osteoporos Int. 2021; 32 (7): 1287–300. DOI: 10.1007/s00198-020-05814-1.
  34. Moore D.M., O'Sullivan M., Kiely P., Noel J., O'Toole P., Kennedy J., Moore D.P., Kelly P. Vitamin D levels in Irish children with fractures: A prospective case-control study with 5 year follow-up. Surgeon. 2021; S1479-666X(21)00067-6. http://dx.doi.org/10.1016/j.surge.2021.02.015
  35. Anderson L.N., Heong S.W., Chen Y. et al.; TARGet Kids Collaboration. Vitamin D and Fracture Risk in Early Childhood: A Case-Control Study. Am. J. Epidemiol. 2017; 185 (12): 1255–62. DOI: 10.1093/aje/kww204.
  36. Gorter E.A., Oostdijk W., Felius A. et al. Vitamin D Deficiency in Pediatric Fracture Patients: Prevalence, Risk Factors, and Vitamin D Supplementation. J Clin Res Pediatr Endocrinol. 2016; 8 (4): 445–51. DOI: 10.4274/jcrpe.3474.
  37. Купцова Т., Кислов А., Струков В. и др. Остео-вит D3 в лечении детей с повторными переломами костей при остеопорозе. Врач. 2016; 1: 46–7. [Kuptsova T., Kislov A., Strukov V. et al. Osteo-vit D3 in the treatment of children with recurrent bone fractures in osteoporosis. Vrach. 2016; 1: 46–7 (in Russian)].
  38. Дедов Д.В. Остеопороз у пациентов различных возрастных групп: клинико-патогенетические аспекты и лечение с применением препаратов Остеомед, Остео-Вит D3 и Остеомед Форте. Врач. 2021; 9: 64–7. [Dedov D.V. Osteoporosis in patients of different age groups: clinical and pathogenetic aspects and treatment with Osteomed, Osteo-Vit D3 and Osteomed Forte. Vrach. 2021; 9: 64–7. https://doi.org/10.29296/25877305-2021-09-13 (in Russian)]
  39. Дедов Д.В. Сравнение эффективности препаратов Остеомед, Остеомед Форте и Остео-Вит D3 в профилактике остеопорозных переломов различной локализации. Врач. 2021; 10: 80–3. [Dedov D.V. Comparison of the effectiveness of Osteomed, Osteomed Forte and Osteo-Vit D3 in the prevention of osteoporotic fractures of various localizations. Vrach. 2021; 10: 80–3. https://doi.org/10.29296/25877305-2021-10-16 (in Russian)]
  40. Дедов Д.В. Применение препаратов Остеомед, Остеомед Форте и Остео-Вит D3 у пациентов с остеопорозом: комплексное лечение и профилактика переломов. Врач. 2021; 12: 83–5. [Dedov D.V. Application of Osteomed, Osteomed Forte and Osteo-Vit D3 in patients with osteoporosis: comprehensive treatment and prevention of fractures. Vrach. 2021; 12: 83–5. https://doi.org/10.29296/25877305-2021-12-14 (in Russian)]